



28 June 2021

**Avacta Group plc**

("Avacta" or "the Group" or "the Company")

**Result of Annual General Meeting**

Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that all resolutions have been duly passed by shareholders at the Annual General Meeting held today.

The full text of each resolution is set out in the Notice of Annual General Meeting, included in the 2020 Annual Report, which is available under the Investor Documents & Presentations section of the Company's website [www.avacta.com](http://www.avacta.com).

Given shareholders were advised not to attend the Annual General Meeting as a result of the Coronavirus pandemic and Government guidance, the Company would like to advise shareholders that the most recent business updates and presentations can be found under the Investor Documents & Presentations section of the Company's website [www.avacta.com](http://www.avacta.com).

**-Ends -**

**For further information from Avacta Group plc, please contact:**

**Avacta Group plc**

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

Michael Vinegrad, Group Communications Director

Tel: +44 (0) 844 414 0452

[www.avacta.com](http://www.avacta.com)

**Stifel Nicolaus Europe Limited (Nomad and Broker)**

Nicholas Moore / Nick Adams / Fred Walsh / Ben Maddison

Tel: +44 (0) 207 710 7600

[www.stifel.com](http://www.stifel.com)

**FTI Consulting (Financial Media and IR)**

Simon Conway / Stephanie Cuthbert

Tel: +44(0) 203 727 1000

[Avacta.LS@fticonsulting.com](mailto:Avacta.LS@fticonsulting.com)

**Zyme Communications (Trade and Regional Media)**

Katie Odgaard

Tel: +44 (0)7787 502 947

[katie.odgaard@zymecommunications.com](mailto:katie.odgaard@zymecommunications.com)

**About Avacta Group plc - <https://www.avacta.com>**

Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.

The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of \$100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance on an animal's immune response; poor specificity in many cases; their large size, complexity and high cost of manufacture.

Avacta's pre|CISION targeted chemotherapy platform releases active chemotherapy in the tumour, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these powerful anti-cancer treatments.

The Group comprises two divisions: The therapeutics development activities are based in Cambridge, UK and the Group is generating near-term revenues from Affimer reagents for diagnostics, bioprocessing and research, through a separate diagnostics business unit based in Wetherby, UK.

Avacta's Diagnostics Division works with partners world-wide to develop bespoke Affimer reagents for third party products. The Group is also developing an in-house pipeline of Affimer-based diagnostic assays including the AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test and AffiDX® BAMS™ SARS-CoV-2 Assay in partnership with Adeptrix Inc.

Avacta's Therapeutics Division is addressing a critical gap in current cancer treatment - the lack of a durable response to current immunotherapies experienced by most patients. By combining its two proprietary platforms the Group is building a wholly owned pipeline of novel cancer therapies designed to be effective for all cancer patients. In 2021 Avacta will commence a phase 1 first-in-human, open label, dose-escalation and expansion study of AVA6000 Pro-doxorubicin, the Group's lead pre|CISION™ prodrug, in patients with locally advanced or metastatic selected solid tumours.

Avacta has established drug development partnerships with pharma and biotech, including a research collaboration with ModernaTX, Inc. (formerly Moderna Therapeutics Inc.), a multi-target deal with LG Chem worth up to \$400m, a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators, a partnership with ADC Therapeutics to develop Affimer-drug conjugates and a collaboration with Point Biopharma to develop radiopharmaceuticals based on the pre|CISION™ platform. Avacta continues to actively seek to license its proprietary platforms in a range of therapeutic areas.

To register for news alerts by email go to [www.avacta.com/investor-news-email-alerts](http://www.avacta.com/investor-news-email-alerts)